Analysts Reduce Pfizer’s Target Price in March

Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 5.57% for Pfizer (PFE) based on the company’s closing price on March 18. In 2019, analysts have already revised the company’s target price downward twice, from $45.35 in January to $44.46 in February and then to $44.14 in March.

Analysts’ current consensus recommendation for PFE is a “hold.” To know more about Pfizer’s growth drivers, read What Are the Key Growth Drivers for Pfizer in Fiscal 2019?

Analysts Reduce Pfizer’s Target Price in March

Of the 15 analysts covering Pfizer, two have given it “strong buys,” five have given it “buys,” seven have given it “holds,” and only one has given it a “sell.” The highest target price estimate for Pfizer is $53, and the lowest is $35, which implies significant volatility in analysts’ estimates.

On March 18, Pfizer closed at $41.81, 0.07% higher than its previous closing price, 21.82% higher than its 52-week low of $34.32, and 10.03% lower than its 52-week high of $46.47. The company’s market cap is $242.12 billion.

Based on its closing price on March 18, Pfizer has reported returns of 0.75% in the last week, -0.38% in the last month, and -6.19% in the last quarter. The company has reported returns of -2.43% in the last half year, 14.30% in the last year, and -4.22% year-to-date.

Revenue and EPS estimates

Analysts expect Pfizer’s revenue to see YoY (year-over-year) changes of 0.59% to $12.98 billion in the first quarter, -0.53% to $13.39 billion in the second quarter, -1.40% to $13.11 billion in the third quarter, and -1.96% to $13.7 billion in the fourth quarter of 2019. Analysts also expect Pfizer’s non-GAAP (generally accepted accounting principles) EPS to see YoY changes of -3.00% to $0.75 in the first quarter, -7.35% to $0.75 in the second quarter, -8.32% to $0.72 in the third quarter, and 5.61% to $0.68 in the fourth quarter.

Analysts expect Pfizer’s revenue to see YoY changes of -0.59% to $53.33 billion in 2019, 1.61% to $54.19 billion in 2020, and 4.56% to $56.66 billion in 2021. Analysts also expect Pfizer’s non-GAAP EPS to see YoY changes of -3.19% to $2.90 in 2019, 6.08% to $3.08 in 2020, and 10.06% to $3.39 in 2021.